Notable 52-Week Highs and Lows 8/10: (YELP) (REN) (HWAY) High; (SPWR) (MYGN) (MCHX) Low

August 10, 2016 3:33 PM EDT

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

52-Week High:
  • Yelp (NYSE: YELP) $37.57. Yelp reported Q2 EPS of $0.01, versus the analyst estimate of ($0.07). Revenue for the quarter came in at $173.4 million versus the consensus estimate of $169.82 million. Yelp sees FY2016 revenue of $700-708 million, versus the consensus of $699.8 million.

  • Resolute Energy (NYSE: REN) $12.54. Resolute Energy reported Q2 EPS of ($2.44), which was $2.41 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $35.4 million versus the consensus estimate of $51.56 million.

  • Healthways (Nasdaq: HWAY) $22.76. Healthways reported Q2 EPS of $0.54, which may not compare to the analyst estimate of $0.01. Revenue for the quarter came in at $125 million versus the consensus estimate of $186.88 million. Healthways also announced that Robert E. Dries has been named executive vice president and chief financial officer, effective August 22, 2016

  • Yirendai (NYSE: YRD) $32.85. Yirendai reported Q2 EPS of RMB4.46, versus RMB2.25 reported last year. Revenue for the quarter came in at RMB773.8 million, versus RMB306.2 million reported last year.
52-Week Low:
  • SunPower (Nasdaq: SPWR) $10.15. SunPower reported Q2 EPS of ($0.22), versus the analyst estimate of ($0.24). Revenue for the quarter came in at $420.5 million versus the consensus estimate of $345.08 million. SunPower sees FY2016 revenue of $3-3.2 billion, versus the consensus of $3.3 billion.

  • Myriad Genetics (Nasdaq: MYGN) $19.10. Myriad Genetics reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million. Myriad Genetics sees FY2017 EPS of $1.00-$1.10, versus the consensus of $1.65. Myriad Genetics sees FY2017 revenue of $740-760 million, versus the consensus of $755.5 million.

  • Marchex (Nasdaq: MCHX) $2.71. Marchex reported Q2 EPS of ($0.02), which was in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $34.4 million versus the consensus estimate of $34.97 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Add Your Comment